Matricelf Ltd (MTLF) - Total Assets
Based on the latest financial reports, Matricelf Ltd (MTLF) holds total assets worth ILA10.99K ILA (≈ $29.47 USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore MTLF operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Matricelf Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Matricelf Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Matricelf Ltd for net asset value and shareholders' equity analysis.
Matricelf Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Matricelf Ltd's total assets of ILA10.99K consist of 68.9% current assets and 31.1% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0.5% |
| Accounts Receivable | ILA443.00K | 2.4% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA2.61 Million | 14.2% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Matricelf Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MTLF stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Matricelf Ltd's current assets represent 68.9% of total assets in 2024, an increase from 41.9% in 2019.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2024, down from 39.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 57.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 14.2% of total assets.
Matricelf Ltd Competitors by Total Assets
Key competitors of Matricelf Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Matricelf Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.69 | 8.56 | 12.32 |
| Quick Ratio | 2.69 | 8.56 | 12.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA3.62K | ILA16.48 Million | ILA23.84 Million |
Matricelf Ltd - Advanced Valuation Insights
This section examines the relationship between Matricelf Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.14 |
| Asset Growth Rate (YoY) | -39.2% |
| Total Assets | ILA18.35 Million |
| Market Capitalization | $20.84 Million USD |
Valuation Analysis
Above Book Valuation: The market values Matricelf Ltd's assets above their book value (1.14x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Matricelf Ltd's assets decreased by 39.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Matricelf Ltd (2019–2024)
The table below shows the annual total assets of Matricelf Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA18.35 Million ≈ $49.20K |
-39.24% |
| 2023-12-31 | ILA30.20 Million ≈ $80.98K |
-23.52% |
| 2022-12-31 | ILA39.49 Million ≈ $105.88K |
+36.64% |
| 2021-12-31 | ILA28.90 Million ≈ $77.49K |
+387.01% |
| 2020-12-31 | ILA5.93 Million ≈ $15.91K |
+40.83% |
| 2019-12-31 | ILA4.21 Million ≈ $11.30K |
-- |
About Matricelf Ltd
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. Matricelf Ltd was incorporated in 20… Read more